Latham & Watkins Advises on Keros Therapeutics’ Pricing of Upsized Public Offering of Common Stock

Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, has announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, at a public offering price of US$40.00 per share. The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be US$140.0 million. All of the common stock is being offered by Keros. In addition, Keros has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on January 8, 2024, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by partners Nathan Ajiashvili and Peter Handrinos, with associates Sandy Kugbei, Jie Lin Nai, and Ilan Lavian.